ArticleDiscover oncology2025
Gut microbiota and breast cancer risk: a Mendelian randomization study stratified by ER status.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Obesity-related Metabolic Dysfunction and Triple-negative Breast Cancer: Epidemiologic Signals, Mechanistic Pathways, and Opportunities for Prevention.Current obesity reports · 2026Review
- Obovatol induces apoptosis in breast cancer by downregulating the PI3K/Akt pathway.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe potential causal relationship between gut microbiota (GM) and breast cancer (BC), particularly its estrogen receptor (ER)-positive (ER+) and ER-negative (ER-) subtypes, remains insufficiently characterized.
methodWe conducted a two-sample Mendelian randomization (MR) analysis to examine genetically predicted causal associations between 473 GM features (abundance in stool) and BC, including overall BC (Ncase = 24,270, Ncontrol = 222,078), ER+ BC (Ncase = 14,540, Ncontrol = 221,705) and ER- BC (Ncase = 9,724, Ncontrol = 221,705).
resultThe MR results demonstrated differential causal associations between GM and BC subtypes: For overall BC risk, lower Barnesiella abundance (OR = 0.93; 95%CI 0.88-0.98; P = 0.006) was protective, whereas higher Providencia abundance (OR = 1.30; 95%CI 1.11-1.51; P = 0.0008) increased risk. Among ER+ BC cases, five GM showed significant associations: Dokdonella (OR = 1.38; 95%CI 1.12-1.70; P = 0.0024), Flavonifractor sp900199495 (OR = 0.81; 95%CI 0.69-0.94; P = 0.0054), Rhodanobacter (OR = 1.45; 95%CI 1.10-1.92; P = 0.0087), Ruminococcus (OR = 0.73; 95%CI 0.58-0.92; P = 0.0080), and UBA7177 sp002491225 (OR = 1.33; 95%CI 1.08-1.63; P = 0.0067). In ER- BC, seven GM factors exhibited causal relationships: Bacteroides A plebeius (OR = 0.90; 95%CI 0.84-0.97; P = 0.0077), CAG-273 sp003507395 (OR = 0.89; 95%CI 0.82-0.95; P = 0.0009), CAG-390 sp003523225 (OR = 0.82; 95%CI 0.71-0.95; P = 0.0064), CAG-433 (OR = 0.86; 95%CI 0.78-0.95; P = 0.0030), Chromobacteriaceae (OR = 0.57; 95%CI 0.39-0.83; P = 0.0034), Providencia (OR = 1.48; 95%CI 1.18-1.86; P = 0.0007), and Syntrophorhabdaceae (OR = 1.52; 95%CI 1.14-2.04; P = 0.0050).
conclusionsOur genetically informed MR analysis provides suggestive evidence for the differential causal roles of specific GM in overall, ER + and ER- BC pathogenesis, offering potential biomarkers for therapeutic intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.